Frank Torti Named Acting FDA Commissioner
On January 20, FDA Commissioner Andrew von Eschenback, MD, will step down as commissioner and Frank Torti, MD, will take over as acting commissioner.
On January 20, FDA Commissioner Andrew von Eschenback, MD, will step down as commissioner and Frank Torti, MD, will take over as acting commissioner.
Torti has been the principal deputy commissioner and chief scientist at the FDA since May 2008.
Torti received his BA and MA degrees from Johns Hopkins University, his MD from Harvard Medical School, and his MPH from the Harvard School of Public Health, where he trained in cancer epidemiology and nutrition. He joined Wake Forest University School of Medicine in 1993 as the Charles L. Spurr professor of Medicine, director of the Comprehensive Cancer Center, and chair of the Department of Cancer Biology.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Oligonucleotide Analysis in Pharmaceutical Quality Control
January 14th 2025Melting point determination using ultraviolet-visible (UV-Vis) spectrophotometry can be used as a sequence-specific method for identifying therapeutic oligonucleotides in pharmaceutical quality control. This method offers a simple, highly selective approach to differentiate between isomers and ensure the integrity of oligonucleotide active pharmaceutical ingredients (APIs) and drug products.
